



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

5-HT1AR agonist 1

Cat. No.:	HY-162585
Molecular Formula:	C ₂₄ H ₂₆ N ₄ O ₃
Molecular Weight:	418.49
Target:	5-HT Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	5-HT1AR agonist 1 (Compound A3) emerges as a relatively balanced multi-target activity profile, including 5-HT1AR agonist with an EC ₅₀ value of 34 nM, SERT reuptake inhibitor (IC ₅₀ =12 nM), NET reuptake inhibitor (IC ₅₀ =78 nM) and DAT reuptake inhibitor (IC ₅₀ =135 nM). 5-HT1AR agonist 1 performs significant antidepressant effects and exhibits excellent bioavailability and low clearance in mice, which is promising for research in the field of antidepressant drugs ^[1] .																																																								
IC₅₀ & Target	SERT 12 nM (IC ₅₀)	NET 78 nM (IC ₅₀)	DAT 135 nM (IC ₅₀)																																																						
In Vivo	<p>5-HT1AR agonist 1 (2.5 MG/ KG, I.V. and 10 MG / KG, P.O.) shows excellent oral bioavailability and low clearance in mice^[1]. 5-HT1AR agonist 1 (30 MG/KG, i.p., 30 min) shows the robust antidepressant potential in the forced swimming test in mice, similar to the effect of Vilazodone (HY-14262)^[1]</p> <p>In Vivo pharmacokinetic parameters of 5-HT1AR agonist 1 in ICR mice.^[1]</p> <p>☒☒☒☒☒☒^[1]</p> <table border="1"> <thead> <tr> <th>Route</th> <th>Dose (mg/kg)</th> <th>T_{max} (h)</th> <th>C_{max} (ng/mL)</th> <th>AUC_{last} (ng·h/mL)</th> <th>T_{1/2} (h)</th> <th>CL (mL/min/kg)</th> <th>Vd (L/kg)</th> <th>F (%)</th> </tr> </thead> <tbody> <tr> <td>A3</td> <td>PO.</td> <td>2.07 ± 0.15</td> <td>0.42 ± 0.08</td> <td>4980 ± 1590</td> <td>16913 ± 2451</td> <td>/</td> <td>/</td> <td>147 %</td> </tr> <tr> <td colspan="9">10 mg/kg</td> </tr> <tr> <td></td> <td>IV.</td> <td>2.64 ± 0.50</td> <td>0.08 ± 0.00</td> <td>2633 ± 104</td> <td>2842 ± 142</td> <td>14.62 ± 0.78</td> <td>3.38 ± 0.79</td> <td></td> </tr> <tr> <td colspan="9">10 mg/kg</td> </tr> </tbody> </table> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male ICR mice</td> </tr> <tr> <td>Dosage:</td> <td>2.5 MG/ KG, I.V. and 10 MG / KG, P.O.</td> </tr> </table>								Route	Dose (mg/kg)	T _{max} (h)	C _{max} (ng/mL)	AUC _{last} (ng·h/mL)	T _{1/2} (h)	CL (mL/min/kg)	Vd (L/kg)	F (%)	A3	PO.	2.07 ± 0.15	0.42 ± 0.08	4980 ± 1590	16913 ± 2451	/	/	147 %	10 mg/kg										IV.	2.64 ± 0.50	0.08 ± 0.00	2633 ± 104	2842 ± 142	14.62 ± 0.78	3.38 ± 0.79		10 mg/kg									Animal Model:	Male ICR mice	Dosage:	2.5 MG/ KG, I.V. and 10 MG / KG, P.O.
Route	Dose (mg/kg)	T _{max} (h)	C _{max} (ng/mL)	AUC _{last} (ng·h/mL)	T _{1/2} (h)	CL (mL/min/kg)	Vd (L/kg)	F (%)																																																	
A3	PO.	2.07 ± 0.15	0.42 ± 0.08	4980 ± 1590	16913 ± 2451	/	/	147 %																																																	
10 mg/kg																																																									
	IV.	2.64 ± 0.50	0.08 ± 0.00	2633 ± 104	2842 ± 142	14.62 ± 0.78	3.38 ± 0.79																																																		
10 mg/kg																																																									
Animal Model:	Male ICR mice																																																								
Dosage:	2.5 MG/ KG, I.V. and 10 MG / KG, P.O.																																																								

Administration:	I.V. and P.O., a single dose
Result:	Showed excellent oral bioavailability in mice ^[1]
Animal Model:	C57 mice
Dosage:	30 MG/KG
Administration:	i.p., a single dose
Result:	Significantly reduced immobility time in the forced swimming test in mice, similar to the effect of Vilazodone (HY-14262) ^[1]

REFERENCES

[1]. Zheng J, et al. Synthesis and biological evaluation of multimodal monoaminergic arylpiperazine derivatives with potential antidepressant profile[J]. Eur J Med Chem. 2024 Jun 3;275:116564.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA